News

 

 

‘Smart’ Inhaler System Improves Patient Outcomes in Study

The Smartinhaler system from New Zealand-based Adherium Ltd. connects with an app to monitor medication adherence, usage, and dosage.

Read more about ‘Smart’ Inhaler System Improves Patient Outcomes in Study

NICE recognises Smartinhaler as best practice for asthma care

The National Institute for Clinical Excellence (NICE) has recognised digital platform Smartinhaler as the most effective means of improving asthma medication adherence in new guidance.

Read more about NICE recognises Smartinhaler as best practice for asthma care

Adherium Appoints Digital Health Pioneer to Lead European Business Development

Digital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. - link here

Read more about Adherium Appoints Digital Health Pioneer to Lead European Business Development

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

Business update call scheduled for today at 4:30 p.m. Eastern

Read more about Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

AB-SA01 meets primary endpoints of safety and tolerability and reduces S. aureus bacterial load in all patients

Read more about AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01

Business update call scheduled for January 4, 2017 at 4:30 p.m. Eastern

Read more about AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01

AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of...

Read more about AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Adherium's Smartinhaler selected for multisite study in EU

Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile...

Read more about Adherium's Smartinhaler selected for multisite study in EU

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the third quarter ended...

Read more about AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Quarterly Report and Update from CEO

CEO Shareholder Letter and Quarterly Report Dear Shareholder, link here

Read more about Quarterly Report and Update from CEO

1 2 3 4 5 6 ... 24